MX2020002942A - Variantes de anticuerpos. - Google Patents

Variantes de anticuerpos.

Info

Publication number
MX2020002942A
MX2020002942A MX2020002942A MX2020002942A MX2020002942A MX 2020002942 A MX2020002942 A MX 2020002942A MX 2020002942 A MX2020002942 A MX 2020002942A MX 2020002942 A MX2020002942 A MX 2020002942A MX 2020002942 A MX2020002942 A MX 2020002942A
Authority
MX
Mexico
Prior art keywords
antibody variants
antibodies
tnfa
bind
relates
Prior art date
Application number
MX2020002942A
Other languages
English (en)
Inventor
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MX2020002942A publication Critical patent/MX2020002942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a TNFa y exhiben una unión a FcRn modificada. Los anticuerpos de la invención tienen buenas funciones efectoras o propiedades farmacocinéticas.
MX2020002942A 2017-09-19 2018-09-11 Variantes de anticuerpos. MX2020002942A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17191988.9A EP3456737B1 (en) 2017-09-19 2017-09-19 Antibody variants
PCT/EP2018/074523 WO2019057565A1 (en) 2017-09-19 2018-09-11 Antibody variants

Publications (1)

Publication Number Publication Date
MX2020002942A true MX2020002942A (es) 2020-07-22

Family

ID=59923274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002942A MX2020002942A (es) 2017-09-19 2018-09-11 Variantes de anticuerpos.

Country Status (16)

Country Link
US (2) US12215146B2 (es)
EP (2) EP3456737B1 (es)
JP (3) JP7341127B2 (es)
KR (1) KR102776587B1 (es)
CN (2) CN119409816A (es)
AR (1) AR113069A1 (es)
AU (1) AU2018335083B2 (es)
BR (1) BR112020005398A2 (es)
CA (1) CA3074249A1 (es)
EA (1) EA202090727A1 (es)
ES (1) ES2978167T3 (es)
IL (1) IL272951A (es)
MX (1) MX2020002942A (es)
SG (1) SG11202001465WA (es)
TW (1) TWI818923B (es)
WO (1) WO2019057565A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
CN101111521B (zh) * 2004-12-29 2011-08-24 株式会社柳韩洋行 肿瘤坏死因子-α特异性人源化抗体
EA200701211A1 (ru) 2004-12-31 2007-12-28 Дженентек, Инк. Полипептиды, которые связываются с br3, и их применение
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
AU2013372331A1 (en) 2013-01-10 2015-07-23 Genmab B.V. Human IgG1 Fc region variants and uses thereof
EP3122777B1 (en) * 2014-03-26 2020-12-23 Cell Medica Switzerland AG Binding members to tnf alpha
EP3219726B1 (en) * 2016-03-17 2020-12-02 Tillotts Pharma AG Anti-tnf alpha-antibodies and functional fragments thereof

Also Published As

Publication number Publication date
JP2023109960A (ja) 2023-08-08
US12215146B2 (en) 2025-02-04
IL272951A (en) 2020-04-30
SG11202001465WA (en) 2020-04-29
TWI818923B (zh) 2023-10-21
CN111108122B (zh) 2024-08-20
US20250122275A1 (en) 2025-04-17
CA3074249A1 (en) 2019-03-28
JP2020534000A (ja) 2020-11-26
BR112020005398A2 (pt) 2020-09-29
CN119409816A (zh) 2025-02-11
EP3684808A1 (en) 2020-07-29
WO2019057565A1 (en) 2019-03-28
TW201915019A (zh) 2019-04-16
EA202090727A1 (ru) 2020-06-15
KR20200052307A (ko) 2020-05-14
JP7341127B2 (ja) 2023-09-08
EP3456737B1 (en) 2024-02-14
EP3456737A1 (en) 2019-03-20
KR102776587B1 (ko) 2025-03-07
AU2018335083B2 (en) 2024-11-14
JP7745051B2 (ja) 2025-09-26
US20200255511A1 (en) 2020-08-13
ES2978167T3 (es) 2024-09-06
CN111108122A (zh) 2020-05-05
JP2024161520A (ja) 2024-11-19
AR113069A1 (es) 2020-01-22
AU2018335083A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
IL280004A (en) Antibody molecules that bind pd-l1 and cd137
CU20190109A7 (es) Moléculas de anticuerpo que se unen a cd73
PT3802608T (pt) Anticorpos anti-cd3 e utilizações destes
MA49038A (fr) Anticorps bispécifiques se liant particulièrement à pd1 et lag3
EP3737422A4 (en) ANTIBODY-PROTAC CONJUGATES
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
HUE066651T2 (hu) CD3-t kötõ antitestek
ECSP17040521A (es) Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales
PT3331912T (pt) Fragmentos variáveis introduzíveis de anticorpos e domínios a1-a2 modificados de ligandos de nkg2d, e ligandos de nkg2d não-naturais que se ligam a recetores de nkg2d não-naturais
PT3328889T (pt) Constructos de anticorpos biespecíficos que se ligam a dll3 e cd3
HUE056289T2 (hu) Pirrolobenzodiazepin-antitest konjugátumok
MX2018003196A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
DK3558390T3 (da) Amanitin antistof-konjugater
PL3710484T3 (pl) Przeciwciała wiążące ctla-4 i ich zastosowania
CL2018000043A1 (es) Anticuerpos de unión a tau
PT3592384T (pt) Anticorpos que se ligam especificamente ao il-1r7 humano
PL3402821T3 (pl) Przeciwciało wiążące psma i jego zastosowania
DK3544636T3 (da) Pyrrolobenzodiazepin-antistof-konjugater
EP3733713A4 (en) SPECIFIC ANTIBODY AND USES THEREOF
IL281297A (en) Anti-npr1 antibodies and uses thereof
IL272266A (en) Anti-cd147 antibody
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL284027A (en) Antibodies to pmel17 and conjugates thereof
IL266516A (en) Antibody binding specifically to cd66c and use thereof